A single center, crossover randomised study comparing various formulations of RDX 022 in healthy volunteers
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs RDX 7675 (Primary) ; Polystyrenes
- Indications Hyperkalaemia
- Focus Therapeutic Use
- 21 Nov 2017 According to a company media release, Ardelyx has made the decision to discontinue development of RDX7675, including both the onset-of-action and Phase 3 studies because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial.
- 22 Jun 2016 Results published in Ardelyx media release.
- 12 Jan 2016 New trial record